Skip to content

Who will PrEP be for?

Infection with HIV associated with increased risk of dialysis and end-stage kidney disease

Political leadership on finance and pace of scale-up needed to realise full potential of treatment as prevention

Tenofovir vaginal ring protects monkeys on Depo-Provera against HIV-like virus

James Smith, from US Centers for Disease Control and Prevention, presenting at ICAAC 2013.

Uptake of PrEP may be limited because few gay men think they are at risk of HIV infection

Treating HCV genotypes 2 and 3 in HIV/HCV co-infected people

Paola Nasta, from Spedali Civili di Brescia, presenting at ICAAC 2013.

Engagement: the 2013 PLWHIV Conference

Engagement: the 2013 PLWHIV Conference

Making treatment as prevention a reality for people who inject drugs

Single-tablet regimen improves antiretroviral adherence and reduces hospitalisation

Scott Sutton, from the Dorn Veterans Administration Medical Center and the University of South Carolina, speaking at ICAAC 2013.